Key stats
About Global X Genomics & Biotechnology ETF
Home page
Inception date
Apr 5, 2019
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Global X Management Co. LLC
Distributor
SEI Investments Distribution Co.
GNOM is Global Xs take on biotech, with more of an emphasis on genomics specifically. The fund fleshes out its description of this sector by including companies that derive more than 50% of their revenues from the following five business activities: (i) gene editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics, and/or (v) biotechnology. The fund uses a proprietary natural language processing algorithm to identify and rank eligible firms based on public documents, such as filings and disclosures. Holdings may span the market-cap spectrum and come from across the globe, including some emerging markets. The market-cap-weighted index is reconstituted and rebalanced semi-annually.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.92%
Health Technology92.44%
Health Services7.48%
Bonds, Cash & Other0.08%
Cash0.08%
Stock breakdown by region
North America80.01%
Europe15.79%
Asia4.20%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
GNOM invests in stocks. The fund's major sectors are Health Technology, with 92.44% stocks, and Health Services, with 7.48% of the basket. The assets are mostly located in the North America region.
GNOM top holdings are Alnylam Pharmaceuticals, Inc and Illumina, Inc., occupying 4.84% and 4.50% of the portfolio correspondingly.
GNOM last dividends amounted to 0.01 USD. Six months before that, the issuer paid 0.03 USD in dividends, which shows a 397.96% decrease.
GNOM assets under management is 44.85 M USD. It's risen 9.64% over the last month.
GNOM fund flows account for −37.55 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
GNOM shares are issued by Mirae Asset Global Investments Co., Ltd. under the brand Global X. The ETF was launched on Apr 5, 2019, and its management style is Passive.
GNOM expense ratio is 0.50% meaning you'd have to pay 0.50% of your investment to help manage the fund.
GNOM follows the Solactive Genomics Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
GNOM invests in stocks.
GNOM price has risen by 7.91% over the last month, and its yearly performance shows a −23.15% decrease. See more dynamics on GNOM price chart.
NAV returns, another gauge of an ETF dynamics, showed a −4.52% decrease in three-month performance and has decreased by −19.62% in a year.
NAV returns, another gauge of an ETF dynamics, showed a −4.52% decrease in three-month performance and has decreased by −19.62% in a year.
GNOM trades at a premium (0.15%) meaning the ETF is trading at a higher price than the calculated NAV.